Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H22O3 |
Molecular Weight | 310.3869 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC=C(C=C1)C(=O)CC(=O)C2=CC=C(C=C2)C(C)(C)C
InChI
InChIKey=XNEFYCZVKIDDMS-UHFFFAOYSA-N
InChI=1S/C20H22O3/c1-20(2,3)16-9-5-14(6-10-16)18(21)13-19(22)15-7-11-17(23-4)12-8-15/h5-12H,13H2,1-4H3
Molecular Formula | C20H22O3 |
Molecular Weight | 310.3869 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including:
http://www.wikidoc.org/index.php/Avobenzone | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3fd7fb-4a28-4db8-9a4d-d7fdd2e45daf
Curator's Comment: description was created based on several sources, including:
http://www.wikidoc.org/index.php/Avobenzone | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de3fd7fb-4a28-4db8-9a4d-d7fdd2e45daf
Avobenzone is an oil soluble ingredient used in sunscreen products to absorb the full spectrum of UVA rays. It helps prevent sunburn. Avobenzone works by absorbing the rays and converting them to energy that is less damaging to the skin.
Originator
Approval Year
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.5 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31058986 |
0.81 g 4 times / day multiple, topical dose: 0.81 g route of administration: Topical experiment type: MULTIPLE co-administered: |
AVOBENZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3.1 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31058986 |
0.81 g 4 times / day steady-state, topical dose: 0.81 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
AVOBENZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
45.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/31058986 |
0.81 g 4 times / day steady-state, topical dose: 0.81 g route of administration: Topical experiment type: STEADY-STATE co-administered: |
AVOBENZONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3.7 g 1.3 times / day multiple, topical (median) Recommended Dose: 3.7 g, 1.3 times / day Route: topical Route: multiple Dose: 3.7 g, 1.3 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 3.69 years (range: 0.64-48.15 years) n = 79 Health Status: healthy Age Group: 3.69 years (range: 0.64-48.15 years) Sex: M+F Population Size: 79 Sources: |
Other AEs: Dermatitis, Eczema... |
1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Other AEs: Acne, Dermatitis... Other AEs: Acne (4.8%) Sources: Dermatitis (2.8%) Dry skin (1.2%) Eczema (1.2%) Erythema (1.2%) Pruritus (2%) Rosacea (0.4%) Seborrhea (0.8%) Skin discomfort (1.2%) Sunburn (0.8%) Conjunctivitis (0.8%) Taste perversion (0.4%) |
3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
Other AEs: Dermatitis, Eczema... Other AEs: Dermatitis (2.8%) Sources: Eczema (0.4%) Erythema (0.8%) Skin discomfort (0.8%) Sunburn (1.6%) Conjunctivitis (0.4%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Eczema | 1.3% | 3.7 g 1.3 times / day multiple, topical (median) Recommended Dose: 3.7 g, 1.3 times / day Route: topical Route: multiple Dose: 3.7 g, 1.3 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 3.69 years (range: 0.64-48.15 years) n = 79 Health Status: healthy Age Group: 3.69 years (range: 0.64-48.15 years) Sex: M+F Population Size: 79 Sources: |
Dermatitis | 2.5% | 3.7 g 1.3 times / day multiple, topical (median) Recommended Dose: 3.7 g, 1.3 times / day Route: topical Route: multiple Dose: 3.7 g, 1.3 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 3.69 years (range: 0.64-48.15 years) n = 79 Health Status: healthy Age Group: 3.69 years (range: 0.64-48.15 years) Sex: M+F Population Size: 79 Sources: |
Rosacea | 0.4% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Taste perversion | 0.4% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Conjunctivitis | 0.8% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Seborrhea | 0.8% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Sunburn | 0.8% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Dry skin | 1.2% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Eczema | 1.2% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Erythema | 1.2% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Skin discomfort | 1.2% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Pruritus | 2% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Dermatitis | 2.8% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Acne | 4.8% | 1.6 g 1.1 times / day multiple, topical (median) Recommended Dose: 1.6 g, 1.1 times / day Route: topical Route: multiple Dose: 1.6 g, 1.1 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 35.44 years (range: 12.04-83.43 years) n = 248 Health Status: healthy Age Group: 35.44 years (range: 12.04-83.43 years) Sex: M+F Population Size: 248 Sources: |
Conjunctivitis | 0.4% | 3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
Eczema | 0.4% | 3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
Erythema | 0.8% | 3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
Skin discomfort | 0.8% | 3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
Sunburn | 1.6% | 3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
Dermatitis | 2.8% | 3.1 g 1.2 times / day multiple, topical (median) Recommended Dose: 3.1 g, 1.2 times / day Route: topical Route: multiple Dose: 3.1 g, 1.2 times / day Co-administed with:: ecamsule Sources: octocrylene titanium dioxide |
healthy, 6.69 years (range: 0.5-67.95 years) n = 246 Health Status: healthy Age Group: 6.69 years (range: 0.5-67.95 years) Sex: M+F Population Size: 246 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Multiple chemical sensitivities, including iatrogenic allergic contact dermatitis, in a patient with chronic actinic dermatitis: implications for management. | 1996 Sep |
|
Unexpected photolysis of the sunscreen octinoxate in the presence of the sunscreen avobenzone. | 2005 Mar-Apr |
|
Evaluation of the photostability of different UV filter combinations in a sunscreen. | 2006 Jan 13 |
|
Prediction of estrogen receptor agonists and characterization of associated molecular descriptors by statistical learning methods. | 2006 Nov |
|
Interactions between different solar UVB/UVA filters contained in commercial suncreams and consequent loss of UV protection. | 2006 Sep |
|
The FDA approves new over-the-counter sunscreen. | 2006 Sep-Oct |
|
[Simultaneous determination of 9 ultraviolet absorbers in cosmetics by high-performance liquid chromatography]. | 2007 |
|
Mexoryl: a review of an ultraviolet a filter. | 2007 Sep 15 |
|
Assessing retinol stability in a hydroquinone 4%/retinol 0.3% cream in the presence of antioxidants and sunscreen under simulated-use conditions: a pilot study. | 2008 Mar |
|
Addressing technical challenges associated with the FDA's proposed rules for the UVA in vitro testing procedure. | 2009 Nov-Dec |
|
Chemical allergens stimulate human epidermal keratinocytes to produce lymphangiogenic vascular endothelial growth factor. | 2015 Mar 1 |
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:23:18 UTC 2023
by
admin
on
Fri Dec 15 15:23:18 UTC 2023
|
Record UNII |
G63QQF2NOX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
142401
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
||
|
NCI_THESAURUS |
C851
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
||
|
CFR |
21 CFR 352.10
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB05617MIG
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
45045
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | RxNorm | ||
|
AA-89
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
AVOBENZONE
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
6480
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
G63QQF2NOX
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
51040
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
CHEMBL1200522
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
DTXSID9044829
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
7423
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
G63QQF2NOX
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
274-581-6
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
m2151
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | Merck Index | ||
|
1045337
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
C47406
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
758680
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
4242
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
70356-09-1
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
DB09495
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY | |||
|
100000086882
Created by
admin on Fri Dec 15 15:23:18 UTC 2023 , Edited by admin on Fri Dec 15 15:23:18 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |